Private Equity’s ‘Living Dead’: Thousands of Zombie Firms Comatose Since 2021

Zombie firms are increasingly weighing on US buyout activity: PitchBook estimates 3,332 PE-backed companies are still stuck in sponsor portfolios despite being held for 5+ years, with no deal activity since end-2021. That compares with 13,509 total PE-backed companies in US sponsor portfolios as of June 30. The rising overhang is occurring as tighter credit conditions loom, reinforcing a risk-off backdrop for private M&A.

Analysis

The real transmission channel here is refinancing friction, not headline defaults. When exit markets stay shut, sponsor-backed borrowers stop being equity monetization stories and become carry trades for lenders, which is bad for anyone holding floating-rate credit with short-term funding or mark-to-market sensitivity. That should pressure regional banks, direct lenders, and CLO equity first; the market usually prices this late, once amendment activity and PIK usage start to show up in quarterly data.

The second-order effect is broader than private equity: a frozen portfolio slows M&A, reduces fee pools for loan arrangers, and keeps asset sales off the table for public comparables. Over the next 1-3 quarters that means less transaction revenue for deal-dependent financials and more reserve build risk where sponsor exposure is concentrated. Over 6-18 months, the winners are special situations funds and distressed debt buyers; the losers are lenders paid to “extend and pretend.”

Contrarian view: this is more likely an earnings-duration problem than a systemic event unless labor markets roll over. If the Fed cuts faster or high-yield spreads tighten, sponsors can refinance out the wall and push the pain further right, which would make broad risk-off positioning look premature. The key falsifier is stable non-accruals and tightening loan spreads on the next two bank/credit reporting cycles; without that, the credit repricing thesis stays alive.

Key Decisions for Investors

• Short CBSU into the next earnings / reserve review window as a proxy for sponsor-credit and funding-cost pressure; aim for 8-12% downside if criticized assets or non-accruals tick higher, and cover if management guides to stable credit metrics.
• Short HYG or BIZD over a 3-6 month horizon to express refinancing stress in leveraged loans and private credit; target a modest spread-widening move as the catalyst, but cut risk if HY spreads tighten materially or the Fed signals a faster easing path.
• Pair trade: long EQR / short CBSU for a defensive-vs-credit-sensitive relative value expression if risk appetite weakens; EQR should be less exposed to the refinancing cycle than bank or sponsor-linked credit, but the trade loses if rates fall sharply and cyclicals re-rate.
• Watch special-situations and restructuring beneficiaries (e.g., distressed debt managers) for a longer-duration long, but wait for evidence of higher amendment/PIK activity before entering; this is a 6-18 month idea, not an immediate catalyst trade.